Editorial overview: Vaccines: Reinvigorating therapeutic cancer vaccines.
Curr Opin Immunol
; 76: 102176, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1783265
ABSTRACT
Lessons learned from the rapid deployment of vaccines during the COVID-19 pandemic are reinvigorating the cancer vaccine field. Using delivery platforms including mRNA and synthetic long peptides, recent clinical trials have demonstrated that cancer vaccines are safe, feasible, and can be associated with the generation of antigen-specific memory T cells and, in some cases, durable clinical responses. Despite these advances, fundamental questions remain regarding the optimal delivery platforms and antigen targets to use in cancer vaccines. Ongoing and future studies that harness advances in the identification of novel sources of antigens, the prediction of immunogenic antigens, and the use of single-cell technologies to profile antigen-specific T cells will hopefully reveal correlates with clinical outcomes and provide a mechanistic basis for future progress.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cancer Vaccines
/
COVID-19
/
Neoplasms
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Curr Opin Immunol
Journal subject:
Allergy and Immunology
Year:
2022
Document Type:
Article
Affiliation country:
J.coi.2022.102176
Similar
MEDLINE
...
LILACS
LIS